ARDX Oct 2024 6.000 call
| Previous Close | 1.5000 |
| Open | 1.4000 |
| Bid | 1.3000 |
| Ask | 1.7500 |
| Strike | 6.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 1.3100 - 1.4200 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 4.21k |
GlobeNewswireArdelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-execut
- GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time
- GlobeNewswire
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA® (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment
